This Formulation Outperforms HIIT for Vascular Health

[00:08] published preprint of a clinical trial for Novosc core. The result showed improvements in human physiological function, particularly related to cardiovascular health.

[00:20] Now, before we get into the three key markers the researchers tracked, a quick bit of transparency. I am an affiliate of Novosc. I've partnered with them for a while and spoken with the CEO and head of R&D on the channel before.

[00:34] In the trial, they did not look at a single biomarker. Rather, they were targeting a multi-pathway strategy that addresses the root biology of aging to improve how our organs actually function as we get older.

[00:48] To understand the significance of this trial, we first have to look at why the researchers chose to focus on the vascular system. In longevity science, vascular aging is considered one of the earliest and most

[01:00] measurable reflections of our overall biological age. It's often said that you are as old as your arteries. Cardiovascular disease remains the leading age-related cause of death

[01:12] globally, responsible for significantly more mortality than cancer. The challenge is that the vascular system begins to change long before we notice it. We see a gradual loss of endothelial

[01:25] responsiveness, which is the ability of our blood vessels to dilate, and an increase in arterial stiffness. These changes emerge in our 40s and 50s, often while our standard blood panel still looks normal.

[01:39] The concept here is that if we can support these systems early and maintain that youthful flexibility, we can potentially preserve resilience across the entire body. In this trial, the researchers weren't

[01:52] looking at sick patients. They were looking at healthy adults aged 40 and older to see if they could actually move the needle on these fundamental markers. To evaluate the impact of the formulation, the researchers conducted a

[02:07] randomized, double-blind, placebo-controlled trial. The duration was 6 months. The participants were 61 healthy adults The participants were 61 healthy adults age 40 or older. 33 in the intervention

[02:19] group and 28 in the placebo group. The intervention was 15 g of Novascore daily versus a non-active placebo. To be taken in a glass of water or juice. The time of day was not specified.

[02:34] The study was conducted independently by researchers at the University of Surrey in the UK, led by Professor Christian Heiss. It's also important to note that the trial was registered in advance on

[02:47] which is a standard procedure to ensure that all planned outcomes are reported transparently. The intervention used was Novascore, which is essentially a coordinated system of 12 ingredients.

[03:03] Here are the ingredients. This list was taken from the paper rather than the Novas website, which is why it has the preprint watermark. Rather than focusing on a single molecule, the hypothesis behind this

[03:15] formulation is that because aging is driven by multiple biological markers, such as oxidative stress, mitochondrial dysfunction, and cellular senescence, a multi-target strategy is required to see a systemic

[03:29] effect. The researchers focused on three independent markers of vascular health. These are some of the most validated metrics we have for assessing the biological age and health of the

[03:42] cardiovascular system. But first, a little explanation of the They measured the baseline and then 1 hour after taking the supplement. And hour after taking the supplement. And finally, 24 hours after the last dose at

[03:57] This is important as the two measures are showing different things. The first, after 1 hour, shows the immediate impact of the supplement while it's still in The second set of measurements were taken after most, if not all of the

[04:13] supplement was out of the system and so was showing more permanent changes that had happened over the 6 months. How long these changes will last after the supplement is stopped is not covered in this trial.

[04:26] With that said, let's look at the statistical significant improvements statistical significant improvements observed over the 6-month period. First is flow-mediated dilation or FMD. This measures how well your blood

[04:39] vessels can widen in response to blood flow and is measured as a percentage. This percentage represents how much the vessels dilate under a stimulus. The results in the paper are absolute changes in FMD, not percentage changes

[04:56] in the baseline value. After 1 hour, they saw a 3.6% increase. And after the 6 months, the study observed a +2.9% improvement compared to

[05:08] the placebo group. For reference, the original baseline FMD was around 5.5%. So, this change represents about a 47% difference. To put that in perspective, a 1% increase in FMD is often associated in

[05:24] literature with a significant reduction in cardiovascular risk. The researchers noted that these results were two or three times greater than what is typically reported for a single intervention like beetroot juice, cocoa

[05:36] flavanols, or tea polyphenols. In fact, this magnitude of improvement rivaled the effects typically seen in training.

[05:48] The marker is pulse wave velocity or PWV. This is essentially a measure of how stiff or flexible your arteries are. The 1-hour measure in the treatment group showed a drop of 0.78 m/s. While

[06:02] group showed a drop of 0.78 m/s. While there was a difference of minus 1.18 m/s compared to the placebo group after 6 months. Arterial stiffness generally increases as we age, typically by about 1 m/s per

[06:15] as we age, typically by about 1 m/s per decade. So a reduction of 1.18 m/s is quite substantial. This result exceeds what has been reported for common longevity supplements like CoQ10, resveratrol, or

[06:29] And is more comparable to the effects seen with intensive exercise or significant weight loss. Finally, the study tracked systolic blood pressure. At the 1-hour they saw a decrease of 4.8

[06:44] mm of mercury in the intervention group, while the placebo increased by 5.5 mm of mercury. Giving a difference of 9.9. It is not clear why the placebo group saw an increase in blood pressure over

[06:59] But the intervention group in any case saw an absolute decrease. At the 6-month mark, the intervention had a reduction of 8.5 mm of mercury. And the placebo had a decrease of 1.5, leaving a placebo-adjusted reduction of

[07:16] 6.1. What is particularly interesting here is that these participants were already in the normal range. They didn't have clinical hypertension. Seeing a drop of 6 mm of mercury in a healthy population

[07:29] is rare. It outperformed the typical result seen with magnesium supplementation, sodium reduction, or even high-intensity interval training. One of the most striking aspects of these results is that all three of these

[07:42] vascular markers, function, stiffness, and pressure improve simultaneously. In clinical research, it's highly unusual to see a single nutritional intervention move the needle on all three of these metrics at once.

[07:55] So, why did this coordinated shift happen? The researchers suggest it's because vascular aging is a multi-pathway problem. It isn't driven by just one factor. It's a combination of oxidative stress, chronic low-grade

[08:08] inflammation, and a decline in mitochondrial function within the endothelial cells. Because the formulation was designed to address these upstream biological hallmarks of the same time, it appears

[08:20] to create a synergistic effect that a single ingredient can't match. There is also an important detail regarding lipids. The study found that these vascular benefits occurred without any significant changes in cholesterol

[08:34] or lipid levels. This is a key finding because it suggests that the improvements weren't just a side effect of lowering cholesterol. Instead, the of lowering cholesterol. Instead, the data indicates that the formulation is

[08:46] working directly on the vascular mechanisms themselves, improving the health and responsiveness of the arterial walls from the inside out. It's a direct intervention in the biology of the blood vessels rather than

[08:58] a modification of metabolic markers like LDL. So, what does this all mean? As noted at the beginning, this is a preprint, so it's not peer-reviewed at this point. It's also quite a small

[09:10] study with around 60 participants. I think it's great to see concrete, while acknowledging the obvious companies which are willing to invest in third-party research to test the

[09:24] efficacy of their products. I also like the multi-supplement approach. However, I want to be very clear about where this fits into the bigger picture. My philosophy has always been that

[09:36] lifestyle comes first. Sleep, nutrition, and consistent movement are the foundations. Small molecules and supplements can help, but they are optimizers. They're not going to make a massive difference. Also, no supplement

[09:50] is going to be a magic pill. I think at the most it will make an incremental improvement. Not that this should be trivialized. Anything that helps extend health span is worth considering. What I do believe

[10:03] is that aging, as currently understood, is multifactorial. Because it's not just one thing going wrong. A multi-supplement strategy that addresses several biological hallmarks at once simply makes more scientific sense to me

[10:17] than isolated ingredients. Healthy aging deserves a higher scientific standard. This study is a step in that direction, focusing on measured physiological results. Thanks for watching, and I will see you all

[10:30] for watching, and I will see you all again soon.